Implantica publishes Interim Report Q3 2022
The RefluxStop™ Commercialisation Strategy updateSignificant events in the third quarter of 2022 · University of York’s Health Economics Consortium in the UK made an in-depth and robust health economic analysis of RefluxStop™ versus Standard of Care and other alternative treatment options. The analysis clearly showed improved incremental cost-effectiveness ratios (ICERs) of RefluxStop against other anti-reflux interventions. The outcome of this assessment highlights RefluxStop™, as a better treatment option compared to the other therapies in quality-of-life outcomes. · Implantica